Orthocell

08/01/2026

Join Orthocell at the 2026 AAHS, ASPN, and ASRM annual meetings in California.

Find us at Booth #115. Meet our experts. Ask questions. See Remplir™ up close.

We also invite you to our Industry Forum. A focused session on regenerative medicine and peripheral nerve repair, with lunch. 1.00 pm–2.30 pm, 15 January 2026, Ga***rd Pacific Resort, Chula Vista, California - in the Port 3 Ballroom.

If you are attending AAHS, ASPN, or ASRM, do not miss this.

Visit the stand.
Join the discussion.
Advance nerve repair.

$OCC

08/01/2026

📺 2026 – The Road Ahead

Stockhead has published this concise summary video recapping Orthocell’s key milestones from the past year, including continued global scaling of our leading nerve repair technologies and expansion into key international markets, including the United States.

Watch to learn more about our ambitions for the year ahead
👉 https://bit.ly/4jFIQ8j

$OCC

06/01/2026

Orthocell Limited (ASX:OCC) has commenced 2026 with another strong result, delivering its seventh consecutive quarter of record revenue.

For the quarter ended 31 December 2025, the Company achieved record quarterly revenue of $3.2 million, representing a 7.0% increase on the prior quarterly record and a 45.2% increase on the prior corresponding period. This outcome reflects a compound quarterly growth rate of 10.4% since Q3 FY24.

Orthocell CEO and MD, Paul Anderson, said:

“The seventh consecutive record revenue result for the December quarter is particularly pleasing, driven by strong performance in existing markets and early Remplir unit sales in the U.S. Early U.S. results show our hybrid market entry strategy, combining specialist distributors with internal field leadership, is successful and delivering positive momentum. With the U.S. momentum building and Canada coming online, we see significant upside as we replicate the successful Australia and Singapore approach on a larger scale in the U.S.”

🔗 Read the ASX release: https://bit.ly/44VCqMd

$OCC

31/12/2025

2025 marked a defining year for Orthocell – from FDA clearance of Remplir to advancing our global footprint, growing clinical evidence and strengthening our commercial foundations. Here’s a look at the highlights powering our momentum in 2026.

30/12/2025

2025 – Year in Review

In July 2022, time stopped for Jasmine (Jas) McGough.

The vibrant 14-year-old from Perth was doing what she loved most, riding her mountain bike on a trail with her family in Margaret River, when she hit a log and fell in a particularly harsh position on her back - acquiring a severe spinal cord injury.

The injury left her unable to move her arms or hands. Her once active life was suddenly replaced by months of uncertainty, rehabilitation and the fear that she might never regain meaningful function.

After undergoing nerve-transfer surgery with Remplir, Jas has regained movement, coordination and sensation that she once thought may be impossible. Rehabilitation is a long journey, but her progress, inspiring.

Her recovery was featured on 7News earlier this year, highlighting the profound patient impact behind our technology.

Since obtaining FDA clearance, Remplir is now helping more people around the world to restore capability and confidence after severe nerve injury.

Watch Jas’ story:

Enjoy the videos and music you love, upload original content, and share it all with friends, family, and the world on YouTube.

28/12/2025

2025 – Year in Review

Remplir FDA clearance marked a defining moment for Orthocell in 2025 – but the true impact of this medical innovation is measured in stories like Liam’s.

At just 17, Liam sustained a devastating spinal injury that left him a quadriplegic, and without the functional use of his hands. After undergoing nerve-transfer surgery supported by Remplir, he has regained strength, dexterity and independence.

His remarkable recovery was featured nationally on Nine News earlier this year, shining a national spotlight on the patients whose lives are being reshaped by advances in nerve repair.

Watch Liam’s story:

Enjoy the videos and music you love, upload original content, and share it all with friends, family, and the world on YouTube.

23/12/2025

Dr. Marc L. Nevins, who leads a world-class periodontics practice in Boston, Massachusetts, presented to the Orthocell team on how he uses Striate+ to achieve incredible outcomes for challenging cases.

Marc leads a team at the Nevins Dental Center that is setting new standards of excellence in periodontics and implant dentistry. He is also an a Fellow of the American Academy of Aesthetic Dentistry, and was recognized as the recipient of the prestigious 2023 American Academy of Periodontology Master Clinician Award.

The whole team Orthocell are hugely grateful for the time Dr. Marc L. Nevins took, out of his family holiday in Australia, to visit our laboratories, where we manufacture Striate+. We were amazed to see in his presentation, some of the truly incredible transformations he is making for his patients that are truly life-changing.

19/12/2025

We are heading to the American Association for Hand Surgery, American Society for Peripheral Nerve, and American Society for Reconstructive Microsurgery 2026 annual meetings.

Join Orthocell on the exhibition floor. Visit us at Booth #115 and see Remplir™ up close.

We are also hosting a dedicated Industry Forum: What Links Regenerative Medicine and Peripheral Nerve Repair? A Biomaterial Built to Solve Real Surgical Challenges.

📍 Ga***rd Pacific Resort, Port 3 Ballroom
🗓 15 January 2026
⏰ 1.00pm–2.30pm

Come for lunch. Hear from experienced surgeons. Explore real-world clinical insights. Discover how innovations in regenerative medicine are transforming peripheral nerve repair.

If you are attending AAHS, ASPN, or ASRM, this session is for you.

Stop by the stand. Join the forum. Be part of the conversation.

14/12/2025

Orthocell has submitted a regulatory application to the British Standards Institution (BSI) seeking approval to commercially distribute Remplir™ in the European Union and United Kingdom, a combined nerve repair market valued at approximately US$750 million and comprising an estimated 500,000 peripheral nerve repair procedures each year.

The application seeks CE and UKCA certification under EU and UK Medical Device Regulations (MDR), with regulatory approval expected in the third quarter of calendar year 2026.

This submission is supported by compelling real-world clinical evidence from Orthocell’s recent Remplir post-market clinical follow-up study, which demonstrated an overall treatment success rate of 81.1% across nerve repair procedures. The data forms a critical component of the technical documentation required for MDR certification.
Orthocell CEO and MD, Paul Anderson said

“We are thrilled to submit our EU and UK regulatory application for Remplir, marking an important milestone in our global expansion strategy. The application is underpinned by the compelling 81.1% treatment success rate from our recent Real World Evidence study, together with previously published clinical data and rapidly increasing surgeon use.

“We expect to receive clearance from the BSI in 3Q of CY 2026 and in the interim, we’ll be focused on advancing our go-to-market strategy to be prepared to generate sales as soon as possible thereafter. The EU and UK has the potential to be our second largest market after the US and is therefore a pivotal component of our global expansion strategy.”

🔗Read the ASX release: https://bit.ly/48Dr55N

$OCC

09/12/2025

Orthocell has announced that it has completed the first commercial sales of Remplir™ in Hong Kong, representing a key milestone in the Company’s Asian growth strategy.

These initial sales follow the successful introduction of Remplir in Hong Kong, including its first surgical use and strong reception at the Hong Kong Orthopaedic Association (HKOA) 45th Annual Congress. These first sales to MontsMed provide immediate in-market availability and are expected to support multiple downstream sales as surgeons adopt the technology.

Hong Kong represents a strategically important entry point into the Guangdong–Hong Kong–Macao Greater Bay Area (GBA), one of Asia’s most dynamic healthcare regions with a population of approximately 100 million people.

Orthocell’s Chief Scientific Officer, Professor Minghao Zheng, is currently in Hong Kong delivering distributor onboarding and scientific training with the MontsMed team. This program is designed to support MontsMed’s early commercial activities by empowering clinical and sales teams to drive engagement with specialist surgeons.

Orthocell CEO and MD, Paul Anderson said:

“First Hong Kong sales represent an important commercial milestone for Orthocell and a strong validation of Remplir’s clinical value. We are well positioned to support MontsMed in driving adoption across leading hospitals in Hong Kong and the Greater Bay Area. We are executing our commercialisation strategy with discipline, and today’s achievement marks another step forward in establishing Remplir as a new standard of care in peripheral nerve repair.”

🔗Read the ASX release: https://bit.ly/4ppRB8t

$OCC

26/11/2025

🖥️ Ausbiz Capital | Investor Connect webinar

Orthocell CEO & MD, Paul Anderson, will be presenting at the Ausbiz Capital Investor Connect Session on Thursday 27 November at 1.00 PM (AEDT).

This free virtual event brings together CEOs from ASX-listed companies to share progress updates and engage directly with the Ausbiz investor community.

Paul will share an update on Orthocell’s commercialisation progress, regulatory plans, and the opportunities ahead as we advance our world-leading regenerative medicine products.

When: 27 November 2025 at 1:00 PM Sydney (AEDT) / 10am Perth (AWST)
🔗 Register to attend: https://info.ausbiz.com.au/connectnov25

$OCC

20/11/2025

Momentum is growing for Remplir™ in nerve-sparing prostate cancer surgery, with around 100 surgeries now performed using the flagship nerve repair device.

Adoption among Australian urologists is accelerating, with Remplir being used to support postoperative nerve protection and recovery. Surgeons are applying the collagen wrap during robotic-assisted radical prostatectomy with the aim of improving erectile function and urinary continence following surgery.

This emerging application represents a significant commercial opportunity, with the potential to expand Orthocell’s U.S. total addressable market from US$1.6B to approximately US$2B.

To support this opportunity, Orthocell is setting up a commercialisation advisory board and investing in further research to strengthen the scientific evidence base for this new application of Remplir.

Initial clinical performance data from nerve-sparing procedures using Remplir across Australia will be released once compiled.

Orthocell CEO and MD, Paul Anderson, said:
“We’re thrilled to see Remplir being adopted by urologists in Australia for nerve-sparing prostate surgery, reflecting its broader potential in peripheral nerve protection and repair. This demonstrates the utility of the product and represents the potential for a meaningful step forward in improving patient outcomes following these complex surgeries.”

Read the ASX release: https://bit.ly/4piU1W1

$OCC